- Home
- PRAX vs NXRT Comparison
PRAX vs NXRT Comparison
Compare PRAX & NXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- NXRT
- Stock Information
- Founded
- PRAX 2015
- NXRT 2014
- Country
- PRAX United States
- NXRT United States
- Employees
- PRAX N/A
- NXRT N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- NXRT Real Estate Investment Trusts
- Sector
- PRAX Health Care
- NXRT Real Estate
- Exchange
- PRAX Nasdaq
- NXRT Nasdaq
- Market Cap
- PRAX 950.8M
- NXRT 875.3M
- IPO Year
- PRAX 2020
- NXRT N/A
- Fundamental
- Price
- PRAX $46.85
- NXRT $34.70
- Analyst Decision
- PRAX Strong Buy
- NXRT Hold
- Analyst Count
- PRAX 9
- NXRT 6
- Target Price
- PRAX $94.44
- NXRT $40.88
- AVG Volume (30 Days)
- PRAX 388.4K
- NXRT 180.3K
- Earning Date
- PRAX 08-04-2025
- NXRT 10-28-2025
- Dividend Yield
- PRAX N/A
- NXRT 5.87%
- EPS Growth
- PRAX N/A
- NXRT N/A
- EPS
- PRAX N/A
- NXRT N/A
- Revenue
- PRAX $7,765,000.00
- NXRT $254,446,000.00
- Revenue This Year
- PRAX N/A
- NXRT N/A
- Revenue Next Year
- PRAX $25.00
- NXRT $4.22
- P/E Ratio
- PRAX N/A
- NXRT N/A
- Revenue Growth
- PRAX 338.45
- NXRT N/A
- 52 Week Low
- PRAX $26.70
- NXRT $29.98
- 52 Week High
- PRAX $91.83
- NXRT $48.31
- Technical
- Relative Strength Index (RSI)
- PRAX 47.63
- NXRT 62.87
- Support Level
- PRAX $44.13
- NXRT $32.97
- Resistance Level
- PRAX $47.06
- NXRT $34.70
- Average True Range (ATR)
- PRAX 2.18
- NXRT 0.71
- MACD
- PRAX 0.05
- NXRT 0.26
- Stochastic Oscillator
- PRAX 54.73
- NXRT 95.80
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.